ACTA1 and breast cancer: In contrast, using the same α-SMA as a marker of identification, cCAFs were previously identified by Ao et al. in 88.2% of metastatic BC patients and in 23.1% of local BC patients, whereas Ortiz-Otero et al. detected cCAFs in all metastatic BC patients [6,29].